The current financial score of AC Immune SA is 5.50. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 18.73M, representing a year-over-year increase of 1058.49%, while its net profit experienced a year-over-year increase of 108.85%.
The current valuation score of AC Immune SA is 8.01. Its current P/E ratio is -3.22, which is -36.75% below the recent high of -2.04 and -145.58% above the recent low of -7.91.
The current earnings forecast score of AC Immune SA is 9.50. The average price target is 9.08, with a high of 12.00 and a low of 5.40.
The current price momentum score of AC Immune SA is 3.52. Currently, the stock price is trading between the resistance level at 2.92 and the support level at 2.49, making it suitable for range-bound swing trading.
The current institutional shareholding score of AC Immune SA is 3.00. The latest institutional shareholding proportion is 26.32%, representing a quarter-over-quarter decrease of 9.41%. The largest institutional shareholder is James Simons, holding a total of 840.13K shares, representing 0.00% of shares outstanding, with 21.06% increase in holdings.
The current risk assessment score of AC Immune SA is 3.34. The company's beta value is 1.61. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.